Cited by

• Economic impact of individualized antimicrobial dose optimization in the critically ill patient in Spain.

  Grau S, Luque S, Ferrandez O, Benitez Cano A, Rubio-Rodríguez D, Rubio-Terrés C. Grau S, et al. Front Pharmacol. 2025 Feb 26;16:1506109. doi: 10.3389/fphar.2025.1506109. eCollection 2025. Front Pharmacol. 2025. PMID: 40078287 Free PMC article.
• Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.

  Gil JM, Rubio-Terrés C, Del Castillo A, González P, Canorea F. Gil JM, et al. Clin Transl Oncol. 2006 May;8(5):339-48. doi: 10.1007/s12094-006-0180-z. Clin Transl Oncol. 2006. PMID: 16760009
• [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].

  Escolar-Albaladejo G, Barón-Esquivias G, Zamorano JL, Betegón-Nicolás L, Canal-Fontcuberta C, de Salas-Cansado M, Rubio-Rodríguez D, Rubio-Terrés C. Escolar-Albaladejo G, et al. Aten Primaria. 2016 Jun-Jul;48(6):394-405. doi: 10.1016/j.aprim.2015.04.012. Epub 2016 Jan 30. Aten Primaria. 2016. PMID: 26832316 Free PMC article. Spanish.
• Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain.

  Bernardo M, Ramón Azanza J, Rubio-Terrés C, Rejas J. Bernardo M, et al. Clin Drug Investig. 2006;26(8):447-57. doi: 10.2165/00044011-200626080-00003. Clin Drug Investig. 2006. PMID: 17163277
• Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.

  Grau S, Pozo JC, Romá E, Salavert M, Barrueta JA, Peral C, Rodriguez I, Rubio-Rodríguez D, Rubio-Terrés C. Grau S, et al. Clinicoecon Outcomes Res. 2015 Oct 13;7:527-35. doi: 10.2147/CEOR.S91587. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 26508881 Free PMC article.